While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide in obesity, rather than filing on the strength of its first, positive study.

Emily Hochberg is a writer and editor with over 15 years of experience specializing in travel, lifestyle, home, parenting, and reviews. In addition to Travel + Leisure, her work appears in ...

In November 2023, the Food and Drug Administration (FDA) approved Zepbound (tirzepatide) for long-term weight management. Tirzepatide has been approved for treating type 2 diabetes under the trade ...

Tirzepatide is under clinical development by Eli Lilly and Co and currently in Pre-Registration for Obstructive Sleep Apnea. According to GlobalData, Pre-Registration drugs for Obstructive Sleep Apnea ...

White T-shirts get a lot of attention, but let’s not forget their equally versatile counterpart: the exceedingly wearable, deceptively simple black T-shirt. It’s a staple you can wear to work ...

Enter GetSimpli Oral Tirzepatide, a revolutionary product that promises to transform your approach to weight loss and metabolic health. Unlike traditional weight loss methods that often involve ...

Mounjaro is the brand name for tirzepatide, and research shows that people with overweight and obesity have lost up to 25% of their body weight on this medication. Social media users have latched onto ...

Although tirzepatide use was associated with elevated amylase and lipase levels, risk for pancreatitis was not elevated among users of tirzepatide vs placebo. Tirzepatide does not yield a significant ...

We may earn a commission through links on our site. Why Trust Us? A GOOD LONG SLEEVE t-shirt is like beer—there are plenty of options that get the job done, but finding truly excellent ones is a ...

The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47%.